BioTech 365

JUNE 30, 2021

ERS Genomics and Nippon Gene sign CRISPR/Cas9 license agreement ERS Genomics and Nippon Gene sign CRISPR/Cas9 license agreement License agreement to enhance Nippon Gene’s CRISPR/Cas9 research reagents offering DUBLIN & TOKYO–(BUSINESS WIRE)–ERS Genomics Limited, which was formed to provide broad … Continue reading →

Genome 40

Genome Genomics Licensing Licensing 40

BioTech 365

JULY 26, 2021

ERS Genomics and Japan SLC Sign CRISPR/Cas9 License Agreement ERS Genomics and Japan SLC Sign CRISPR/Cas9 License Agreement Nobel prize winning CRISPR technology to be applied in development of genetically engineered animal models DUBLIN & SHIZUOKA, Japan–(BUSINESS WIRE)–ERS Genomics Limited, … Continue reading →

Genome 40

Genome Genomics Licensing Licensing 40

BioTech 365

APRIL 19, 2021

ERS Genomics and NUVISAN ICB Sign CRISPR/Cas9 License Agreement ERS Genomics and NUVISAN ICB Sign CRISPR/Cas9 License Agreement CRISPR offerings to enhance NUVISAN’s drug development service portfolio DUBLIN & BERLIN–(BUSINESS WIRE)–ERS Genomics Limited, which was formed to provide broad access … Continue reading →

Genome 40

Genome Genomics Licensing Licensing 40

BioTech 365

MAY 12, 2021

ERS Genomics and GenScript Biotech Corporation sign CRISPR/Cas9 license agreement ERS Genomics and GenScript Biotech Corporation sign CRISPR/Cas9 license agreement License agreement to enhance GenScript’s CRISPR offering for gene and cell therapy research DUBLIN & PISCATAWAY, N.J.–(BUSINESS

Genome 40

Genome Genomics Licensing Licensing 40

BioTech 365

AUGUST 17, 2021

ERS Genomics and Cellular Engineering Technologies Enter CRISPR/Cas9 License Agreement ERS Genomics and Cellular Engineering Technologies Enter CRISPR/Cas9 License Agreement License allows Cellular Engineering Technologies to develop, manufacture and commercialize next generation stem cell lines using CRISPR/Cas9 technology DUBLIN & … Continue (..)

Engineer 40

Engineer Genome Genomics Licensing 40

BioTech 365

MARCH 9, 2021

ERS Genomics and Setsuro Tech Sign CRISPR/Cas9 License Agreement ERS Genomics and Setsuro Tech Sign CRISPR/Cas9 License Agreement Nobel prize winning CRISPR technology to be applied in development of genetically engineered cell and animal models DUBLIN & TOKUSHIMA, Japan–(BUSINESS WIRE)–ERS … Continue reading →

Genome 40

Genome Genomics Licensing Licensing 40

BioPharma Reporter

DECEMBER 3, 2020

ERS Genomics, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by the one of the joint 2020 Nobel Prize winners for Chemistry, Dr Emmanuelle Charpentier, has granted a non-exclusive license agreement to German startup, Vivlion.

Licensing 64

Licensing Licensing Genome Genomics 64

BioTech 365

FEBRUARY 23, 2021

ERS Genomics and G+FLAS Life Sciences sign CRISPR/Cas9 license agreement ERS Genomics and G+FLAS Life Sciences sign CRISPR/Cas9 license agreement G+FLAS Life Sciences is applying CRISPR technology to develop research tools and reagents DUBLIN & SEOUL–(BUSINESS WIRE)–ERS Genomics Limited, which … Continue reading →

Life Science 40

Life Science Genome Genomics Licensing 40

BioSpace

SEPTEMBER 8, 2021

based Precision BioSciences announced a license and collaboration deal with Philadelphia-based iECURE and described its clinical development plans. Durham, N.C.-based

Genome 70

Genome Genomics Licensing Licensing 70

Pharmaceutical Technology

MARCH 28, 2023

Vertex Pharmaceuticals has signed a new non-exclusive licensing agreement with CRISPR Therapeutics to expedite the development of its hypoimmune cell therapies to treat type 1 diabetes (T1D). The gene-editing technology allows for precise, directed changes to genomic DNA. The system comprises the Cas9 enzyme and a guide RNA.

Gene Editing 235

Gene Editing DNA Gene Gene Therapy 235

pharmaphorum

MARCH 24, 2022

LifeMine has developed an industrialised, genomics-based discovery engine that it hopes will take a broad, systematic approach to identifying new compounds from fungi and screening them for activity against disease targets. Image by jggrz from Pixabay . The post GSK partners LifeMine on fungi-derived medicines appeared first on.

Medicine 105

Medicine Genome Genomics Engineer 105

Camargo

NOVEMBER 11, 2020

Unpacking the (Black) Box: Antares Licenses Urology Product with Boxed Warning. In October, Antares Pharma licensed Ferring Pharmaceuticals’ Nocdurna® (desmopressin acetate) sublingual tablet , which was approved in 2018 for the same indication as Noctiva and has a boxed warning highlighting the same risks.

Development 242

Development Bioequivalency Generic Drugs Production 242

BioTech 365

MARCH 1, 2021

ERS Genomics Expands Team With Appointment of Jon Kratochvil as VP Business Development ERS Genomics Expands Team With Appointment of Jon Kratochvil as VP Business Development Jon Kratochvil joins as Vice President for Business Development & Licensing for North America … Continue reading →

Business Development 40

Business Development Genome Genomics Development 40

Pharmaceutical Technology

JULY 22, 2022

In 2020, Sangamo and Novartis signed an exclusive, global licensing collaboration agreement to develop and commercialise genomic therapies for the treatment of neurodevelopmental disorders, including autism. The post Sangamo’s cell therapy receives EC orphan medicinal product designation appeared first on Pharmaceutical Technology.

Medicine 130

Medicine Production Genome Genomics 130

BioTech 365

OCTOBER 13, 2020

Food analysis and biotechnology company licenses gene editing technology DUBLIN & KANAGAWA, Japan–(BUSINESS WIRE)–ERS Genomics Limited (“ERS”), which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, today announced it has … Continue (..)

Genome 40

Genome Genomics Reagent Gene Editing 40

Drug Discovery Today

APRIL 22, 2020

Cambridge, UK, and Brisbane, CA, 21 April 2020 Mogrify Ltd (Mogrify®), a UK company aiming to transform the development of cell therapies by the systematic discovery of novel cell conversions, and Sangamo Therapeutics (Sangamo) (Nasdaq: SGMO), a genomic medicine company, today announced that they have executed a collaboration and exclusive license (..)

Licensing 40

Licensing Licensing Genome Genomics 40

Pharmaceutical Technology

FEBRUARY 26, 2023

Although research here is about 20 years old, it remains new compared to other areas like genomics, says Gilbert. Previously, Takeda had licensed the two Finch treatments FIN-524 and FIN-525 for their development in IBD. Last year, Takeda Pharmaceutical ended its deal with Finch in August after a review of its pipeline.

Bacteria 278

Bacteria Trials Research Medicine 278

pharmaphorum

DECEMBER 5, 2022

That sets up a rolling Biologics License Application (BLA) with the FDA by the end of the year, setting Valneva on course to bring the first chikungunya vaccine to market anywhere in the world. Valneva estimates that the global market for vaccines against chikungunya could exceed $500 million annually by 2032.

Vaccine 98

Vaccine Vaccination Antibody Allergies 98

pharmaphorum

FEBRUARY 11, 2022

” Hopes were high that a drug developed by Sangamo based on its zinc finger nuclease (ZFN) genome-editing technology could lead to the first therapy that could correct the genetic defect n MPS I, but that candidate – called SB-318 – flunked out in a clinical trial reported in 2019 and was discontinued.

Gene Therapy 111

Gene Therapy Gene Trials FDA Approval 111

pharmaphorum

OCTOBER 5, 2022

Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule.

RNA 105

RNA Genetics Dermatology Antibody 105

pharmaphorum

MARCH 25, 2021

The COSMIC (Catalogue of Somatic Mutations in Cancer) database, operated by the Wellcome Sanger Institute, grew out of the work of the Cancer Genome Project and has been gathering data on mutations associated with specific cancers for almost 17 years.

Drugs 59

Drugs Genome Project Genome Genomics 59

pharmaphorum

JULY 14, 2022

“We must, however, recognise the unacceptably difficult journey to get to this point for those affected; ten agonising months since Trodelvy was licensed by the MHRA,” said the patient organisation’s chief executive Baroness Delyth Morgan.

Drugs 104

Drugs Hormones Genome Genomics 104

pharmaphorum

DECEMBER 22, 2020

The latest deals include a license agreement with San Diego-based Ligand Therapeutics , which has a subsidiary producing technology for neurological disorders. The license agreement, together with the biotech’s cash reserves, is enough to fund operations through 2023.

Licensing 52

Licensing Licensing Genetics Sales 52

BioTech 365

SEPTEMBER 29, 2020

NEW YORK, LONDON, & PARIS–(BUSINESS WIRE)–#biopharmaceutical–Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases, announced its launch of Aptorum (..)

Genome 40

Genome Genomics Licensing Licensing 40

The Pharma Data

SEPTEMBER 21, 2020

It will draw on research led by Professor Steven Pollard at the University of Edinburgh, which delved into stem cell biology, synthetic biology and cancer genomics. Cellinta has entered into a collaborative research agreement with the University, and retains the option to license intellectual property developed from research conducted there.

Gene Therapy 52

Gene Therapy Gene Development Genome 52

pharmaphorum

NOVEMBER 12, 2020

In 2018, it bought Element Genomics – a spin-out of Duke University in the US – to add genome-editing technologies, and has also been growing its internal exercise at its Boston R&D hub, although so far it hasn’t advanced and gene therapies into clinical development.

Gene Therapy 52

Gene Therapy Gene Manufacturing Contract Manufacturing 52

XTalks

MAY 20, 2022

In addition, some clinical scientist jobs require you to be licensed or certified. In the US, you can gain these certifications or licenses from: The American Society for Clinical Pathology ( ASCP ). Clinical Pharmaceutical Science. Rehabilitation Engineering. Radiotherapy Physics. Ultrasound and non-ionising radiation. Microbiology.

Scientist 105

Scientist Life Science Clinical Research Doctors 105

pharmaphorum

APRIL 27, 2021

Nevertheless it’s a relief for uniQure and other gene therapy developers, as there is a perennial concern that inserting genes into the genomes of patient cells could inadvertently activate genes that cause cancer. The post FDA lifts hold on uniQure gene therapy after cancer case review appeared first on.

Gene Therapy 52

Gene Therapy Gene Genome Genomics 52

pharmaphorum

SEPTEMBER 28, 2022

” ArsenalBio’s platform makes use of automation, large-scale genome engineering, using technologies like CRISPR-based gene-editing, and machine learning and artificial intelligence algorithms to design, build, and test cell therapies.

Gene Editing 59

Gene Editing Genome Genomics Engineer 59

pharmaphorum

MAY 12, 2022

The alliance will pair BMS’ library with Evotec’s EVO panOmics platform – which uses genomics, transcriptomics, proteomics, and phenotypic data for drug discovery – as well as EVO panHunter, an artificial intelligence software used to analyse the resulting data. billion partnership last week. . billion partnership last week.

Protein 52

Protein Genome Genomics Drugs 52

XTalks

DECEMBER 1, 2020

Fortunately, technological advances — such as those pioneered by Menarini Silicon Biosystems — have allowed researchers and healthcare practitioners to decipher these issues, drilling down to single-cell genomic levels to uncover variations that may account for reduced drug efficacy or biochemical resistance.

Clinical Trials 96

Clinical Trials Clinical Trials Trials Clinical Research 96

Pharmaceutical Technology

FEBRUARY 3, 2023

The field of genomic medicine has reached a true turning point. This is really what has been very challenging for upscaling viral vector production and what leads some companies that have in-licensed projects with a huge amount of viral vector to slightly panic about future production,” she says.

Genome 244

Genome Genomics Medicine Gene Therapy 244

Advarra

FEBRUARY 28, 2023

For example, the Genomic Data Sharing Policy applies to NIH-funded research generating large-scale human or non-human genomic data. If another applicable policy has more detailed expectations than what the DMS policy has, organizations should follow those expectations in addition to the DMS policy.

Research 52

Research Genome Genomics Genotype 52

The Pharma Data

NOVEMBER 3, 2020

It may also allow for priority or rolling review of a company’s Biologics License Application (BLA). LogicBio’s proprietary genome editing technology platform, GeneRide, enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination.

Clinical Trials 40

Clinical Trials Clinical Trials Gene Editing Genome 40

The Pharma Data

NOVEMBER 5, 2020

Most recently, Holland served as Global Head of licensing at Lonza AG. Deep Genomics – Toronto-based Deep Genomics appointed Amanda Kay to the newly-created role of chief business officer. Prior to joining Deep Genomics, Kay was senior vice president of Corporate Development and a member of the executive team at Synlogic, Inc.

Genome 40

Genome Genomics Medicine Life Science 40

Delveinsight

JANUARY 28, 2021

Then, late last year, it aimed COVID-19, turning its genome-based, high-throughput discovery platform for parsing T-cell receptors (TCRs) toward the coronavirus pandemic and how those immune cells reacted and inked a licensing agreement with Qiagen.

Bacteria 52

Bacteria Trials Drugs Clinical Trials 52

The Pharma Data

JANUARY 4, 2021

We believe our allogenic CAR-T platform is significantly stronger with chPD1 target licensed from Longwood University. . Kiromic’s deep understanding of the tumor micro environment (TME) and the tumors’ escape and masking mechanisms led to development of a promising platform for chimeric antigen receptor therapy (CAR-T).

In-Vivo 40

In-Vivo Development Immune Response Big Data 40